Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent surgical resection or local therapy, or have experienced disease progression following prior surgical resection or local therapy.
This description comes directly from the study's public registry record.
Haiyun Zuo · 021-31852088 · Haiyun.zuo@innoventbio.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hosptial of USTC | Hefei, Anhui, China | Recruiting |
| Zhongshan Hospital, Fudan university | Shanghai, Shanghai Municipality, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07490262